Breaking
● GLP-1 trial shows 34% reduction in cardiovascular events over 5 years ● Senolytics drug enters Phase III — first human trial results expected Q1 2027 ● FDA fast-tracks CRISPR base-editing therapy for sickle cell disease ● Longevity biotech index up 12% YTD as institutional capital accelerates ● AI diagnostic platform achieves 97.2% accuracy in early-stage pancreatic cancer detection ● Harvard study links CGM use to 23% lower all-cause mortality in non-diabetics
Impact Health Magazine
The Pulse newsletter morning briefing
The Pulse

The Weekly Health-Wealth Briefing

Every Friday morning, the most important developments in longevity science, health investment, and elite wellness — curated for the world's most discerning readers.

47,000+

Subscribers

68%

Open rate

Friday

Delivery

Free

Always

Every Issue

What You Get Every Friday

The Week in Longevity

The three most important scientific developments you need to know — explained in plain language, with clinical context.

Investment Radar

One healthcare investment thesis, dissected. Biotech, HealthTech, REITs, and PE — the opportunities our editors are watching.

The Protocol

One evidence-based health intervention you can implement this week. Practical, actionable, and grounded in the latest research.

The Disruptor Spotlight

A profile of one founder, physician, or investor reshaping the future of human health.

Recent Issues
Issue #142August 29, 2026The Senolytic Revolution: Why 2027 Could Be the Year Everything Changes
Issue #141August 22, 2026GLP-1 Beyond Weight Loss: The Cardiovascular Data That Changes Everything
Issue #140August 15, 2026The $28 Billion Longevity Bet: Where the Smart Money Is Going
Subscribe

Join 47,000 Health-Wealth Leaders

No spam. No noise. Just the most important health and investment intelligence, delivered every Friday.

Free forever. Unsubscribe anytime. We never share your data.